AT A GLANCE

11/22/2022

Coronavirus Disease 2019 (COVID-19)

Updated twice weekly on Tuesdays and Fridays, and current as of 3:00 p.m. on the date it was posted.

This document is a collation of resources for your reference. For official guidance on COVID-19 in Ontario, please visit the Ministry of Health.

Table of Contents

New Content ........................................................................................................................................... 3
Public Health Agencies ............................................................................................................................ 3
  Public Health Agency of Canada | canada.ca ....................................................................................... 3
  BC Centre for Disease Control | bccdc.ca ......................................................................................... 3
  Institut national de santé publique .................................................................................................... 3
  CDC: Centers for Disease Control and Prevention | cdc.gov ................................................................ 3
  ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu ................................. 4
  FDA: U.S. Food & Drug Administration | fda.gov ........................................................................ 4
  Public Health England | gov.uk .............................................................................................................. 4
  World Health Organization | who.int .................................................................................................. 4
Other relevant government bodies / health care organizations .............................................................. 5
  CIDRAP: Center for Infectious Disease Research Policy | cidrap.umn.edu ........................................ 5
  National Collaborating Centre for Environmental Health | ncceh.ca ....................................................... 5
Updated Daily .......................................................................................................................................... 6
COVID-19 resources (case counts) | arcgis.com ................................................................................ 6
COVID-19 Canada Open Data Working Group | COVID-19 CODWG .................................................. 6
  Johns Hopkins CCSE | systems.jhu.edu ............................................................................................. 6
  NextStrain | nextstrain.org .................................................................................................................. 6
Guidelines and Technical documents (updated weekly) ........................................................................ 6
Section I: General Guidelines ................................................................................................................ 6
  Ontario / Canada Main Page .............................................................................................................. 6
  Reopening/Rebuilding Guidelines .................................................................................................... 6
<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccinations- General</td>
<td>7</td>
</tr>
<tr>
<td>Vaccinations- Specific populations</td>
<td>12</td>
</tr>
<tr>
<td>Vaccinations- Adverse Effects</td>
<td>14</td>
</tr>
<tr>
<td>Background Information/Case Definitions</td>
<td>15</td>
</tr>
<tr>
<td>Laboratories</td>
<td>16</td>
</tr>
<tr>
<td>Miscellaneous Guidelines</td>
<td>17</td>
</tr>
<tr>
<td>Data &amp; Surveillance</td>
<td>18</td>
</tr>
<tr>
<td>Vaccinations – Omicron</td>
<td>19</td>
</tr>
<tr>
<td>Testing</td>
<td>20</td>
</tr>
<tr>
<td>Symptoms/Treatment</td>
<td>22</td>
</tr>
<tr>
<td>COVID-19 Diagnosis in Children</td>
<td>24</td>
</tr>
<tr>
<td>Post-COVID-19 Condition</td>
<td>24</td>
</tr>
<tr>
<td>Case Investigation &amp; Contact Tracing</td>
<td>25</td>
</tr>
<tr>
<td>Infection Prevention and Control</td>
<td>26</td>
</tr>
<tr>
<td>Section II: Guidelines for Health Sectors</td>
<td>27</td>
</tr>
<tr>
<td>Healthcare Providers</td>
<td>27</td>
</tr>
<tr>
<td>Congregate Living (including Long-Term Care, Prisons, and Shelters)</td>
<td>27</td>
</tr>
<tr>
<td>Section III: Guidelines for the Community</td>
<td>29</td>
</tr>
<tr>
<td>Travel, Transport &amp; Borders</td>
<td>29</td>
</tr>
<tr>
<td>Schools / Childcare</td>
<td>29</td>
</tr>
<tr>
<td>Mental Health /Addiction</td>
<td>30</td>
</tr>
<tr>
<td>Community</td>
<td>30</td>
</tr>
<tr>
<td>Businesses/Workplaces</td>
<td>31</td>
</tr>
<tr>
<td>Masks (Non-Medical)</td>
<td>32</td>
</tr>
</tbody>
</table>
**New Content**

**Public Health Agencies**

**Public Health Agency of Canada | canada.ca**


- **Key COVID updates** [11-21-2022]
  - Weekly change in cases: 15,682
  - Total cases: 4,392,747
  - Weekly change in deaths: 268
  - Total deaths: 47,468
- **COVID-19 daily epidemiology update** [updated regularly]
- **COVID-19 data trends** [updated regularly]

**BC Centre for Disease Control | bccdc.ca**

- [Immunization manual: summary of changes: admin circular](https://www.bccdc.ca/en/vaccination-manual?fbclid=IwAR1UuF6e6cI8RJcXUq_dDvK97Nn4dS5WjFtYh5MUAcxZ2_qxLJeeNp5pMk) [updated 11-17-2022]

**Institut national de santé publique | inspq.qc.ca**


**CDC: Centers for Disease Control and Prevention | cdc.gov**

- [Early release: Effectiveness of bivalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection — increasing community access to testing program, United States, September–November 2022](https://www.cdc.gov/mmwr/mmwrhtml/mm7041a4.htm) [11-22-2022]
- [COVID Data Tracker recent updates - 2022-11-17 - a new figure displaying the "Percent of Pregnant People Ages 18-49 Years Who Received an Updated (Bivalent) Booster Dose Before or During Pregnancy Overall, by Race/Ethnicity, and Week Ending Date" was added to the Vaccination Among Pregnant People tab.](https://covid.cdc.gov/covid-data-tracker/external) [11-18-2022]
- [COVID Data Tracker recent updates - 2022-11-17 - the Vaccination Trends tab was updated to display a new metric that displays a daily count of people receiving an updated (bivalent) booster dose by date of vaccine administration.](https://covid.cdc.gov/covid-data-tracker/external) [11-18-2022]
- [COVID Data Tracker recent updates - 2022-11-17 - the Vaccine Confidence tab was updated to include new national survey indicators on bivalent booster uptake and intent to receive bivalent booster among children and teens ages 5-17 years.](https://covid.cdc.gov/covid-data-tracker/external) [11-18-2022]
- **COVID Data Tracker recent updates - 2022-11-17** - A new figure displaying the "Percent of Pregnant People Ages 18-49 Years Who Received an Updated (Bivalent) Booster Dose Before or During Pregnancy Overall, by Race/Ethnicity, and Week Ending Date" was added to the Vaccination Among Pregnant People tab. [11-18-2022]

- **COVID Data Tracker recent updates - 2022-11-17** - The Vaccination Trends tab was updated to display a new metric that displays a daily count of people receiving an updated (bivalent) booster dose by date of vaccine administration. [11-18-2022]

- **COVID Data Tracker recent updates - 2022-11-17** - The Vaccine Confidence tab was updated to include new national survey indicators on bivalent booster uptake and intent to receive bivalent booster among children and teens ages 5-17 years. [11-18-2022]

- **Archive of COVID-19 vaccination data updates** [11-18-2022]

- **ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu**
  - Data on COVID-19 vaccination in the EU/EEA [updated regularly]

- **FDA: U.S. Food & Drug Administration | fda.gov**
  - Coronavirus (COVID-19) update: daily roundup [updated regularly]

- **Public Health England | gov.uk**
  - Note: Public Health England was replaced by UK Health Security Agency and Office for Health Improvement and Disparities. These organizations are listed below under “Other relevant government organizations”
  - Location of Public Health England (PHE) functions from 1 October 2021

- **World Health Organization | who.int**
  - WHO coronavirus (COVID-19) dashboard [updated regularly]
Other relevant government bodies / health care organizations

- Health Canada
  - Health professional risk communication: SPIKEVAX bivalent (original / Omicron BA.4/5) (elasomeran/davesomeran) COVID-19 vaccine with English-only vial and carton labels [11-18-2022]

- Indigenous Services Canada
  - Coronavirus (COVID-19) and Indigenous communities [updated regularly]

- Statistics Canada
  - Individuals with chronic conditions were more likely to experience difficulties accessing health care services during the pandemic than those without chronic conditions [11-16-2022]
  - COVID-19: a data perspective [updated regularly]

- UK Health Security Agency
  - Assessment and procurement of coronavirus (COVID-19) tests [updated 11-22-2022]
  - National flu and COVID-19 surveillance reports published [updated 11-17-2022]
  - COVID-19 test validation approved products [updated 11-17-2022]

- UK Medicines and Healthcare products Regulatory Agency
  - Medical devices given exceptional use authorisations during the COVID-19 pandemic [updated 11-22-2022]

- UK Office for National Statistics

CIDRAP: Center for Infectious Disease Research Policy | cidrap.umn.edu

- US pandemic death toll higher than in 20 peer countries [11-21-2022]
- Imaging spotlights brain changes 6 months after COVID-19 [11-21-2022]
- Myocarditis after mRNA COVID vaccine risk real, but rare in young men [11-21-2022]
- NFL games with many in-person fans may have spiked COVID cases [11-18-2022]
- Flu rises to high levels across most of US [11-18-2022]
- Parental doubt may be driving low COVID vaccine uptake in US kids [11-18-2022]
- Post-COVID epilepsy rare but more common than after flu [11-17-2022]
- Study: Severe COVID less likely in kids of vaccinated parents [11-17-2022]
- New-onset diabetes risk higher in recovering COVID-19 patients [11-17-2022]

National Collaborating Centre for Environmental Health | ncceh.ca

- October research scan with COVID-19 sections [10-20-2022]
- September research scan with COVID-19 sections [09-21-2022]
- August research scan with COVID-19 sections [08-24-2022]

ProMED | promedmail.org
• Latest on COVID-19 [individual posts]

Updated Daily

COVID-19 resources (case counts) | arcgis.com
• Canada COVID-19

COVID-19 Canada Open Data Working Group | COVID-19 CODWG
• COVID-19 in Canada (case count dashboard)

Johns Hopkins CCSE | systems.jhu.edu
• 2019-nCoV Global Cases (by Johns Hopkins CSSE) [real-time tracking]
• Resetting our response: changes needed in the US approach to COVID-19 [07-29-2020]

NextStrain | nextstrain.org
• Phylogeny of SARS-like betacoronaviruses including novel coronavirus (nCoV) [real-time tracking]
• Genomic epidemiology of novel coronavirus (nCoV) [real-time tracking]
• Genomic analysis of nCoV spread. Situation report 2020-01-30 [real-time tracking]

Guidelines and Technical documents (updated weekly)
The guidelines listings are current to 10-26-2022; posted 10-28-2022

Section I: General Guidelines

Ontario / Canada Main Page
• Ontario guidance
• Canadian guidance (federal)

Reopening/Rebuilding Guidelines

Ontario
• ON COVID-19 public health measures and advice [no date]

Canada (federal) and provinces and territories (other than Ontario)
• CA Guidance for a strategic approach to lifting restrictive public health measures [06-10-2022]
• CA COVID-19: readiness criteria and indicators for easing restrictive public health measures [05-14-2021]
• BC B.C.’s response to COVID-19 [updated 10-12-2022]
• AB COVID-19 public health actions [no date]
- SK Living with COVID [no date]
- MB Manitoba Pandemic Response System [no date]
- QC Coronavirus disease (COVID-19) in Québec [08-17-2022]
- NB Living with COVID-19 [no date]
- NL Current Restrictions [no date]
- PEI COVID-19 (coronavirus) in Prince Edward Island [no date]
- NS Reopening plan [updated regularly]
- NW COVID-19 [no date]
- YT Forging ahead: the Yukon's continuing response to COVID-19 [no date]
- NT Nunavut’s Path: Living with COVID-19 [no date]
- Guidance on re-opening northern, remote, isolated, and Indigenous communities [no date]

WHO
- Implementation guidance for assessments of frontline service readiness [07-01-2021]
- Considerations for implementing and adjusting public health and social measures in the context of COVID-19: interim guidance [06-14-2021]

ECDC
- Data on country response measures to COVID-19 [updated 08-25-2022]
- Transitioning beyond the acute phase of the COVID-19 pandemic: approaches and tools used by a sample of EU countries in the transition and de-escalation phase – interim report [04-27-2022]
- Introducing a coherent European framework for tuning COVID-19 response measures [03-17-2021]

Vaccinations- General

Ontario Ministry of Health
- COVID-19 vaccine-relevant information and planning resources [updated 10-17-2022]
- Ethical framework for COVID-19 vaccine distribution [archived] [updated 04-27-2022]

Canada (Federal)
- Updated guidance on COVID-19 vaccine booster doses in Canada [updated 10-07-2022]
- Archived 39: Recommendations on the use of bivalent Omicron-containing mRNA COVID-19 vaccines [updated 10-07-2022]
- COVID-19 drugs and vaccines [updated 09-16-2021]
- Planning guidance for immunization clinics for COVID-19 vaccines [09-22-2022]
- Interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada [06-29-2022]
- Summary of NACI statement of June 29, 2022 [06-29-2022]
- Adjusting public health measures in the context of COVID-19 vaccination [updated 06-27-2022]
- Health care provider vaccine tool kit. version 3 [06-10-2022]
- COVID-19 vaccine guide for youth and adults (12 years and over): Overview [08-11-2022]
• An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) guidance on booster COVID-19 vaccine doses in Canada [12-03-2021]
• Summary of NACI rapid response of December 3, 2021: guidance on booster COVID-19 vaccine doses in Canada [12-03-2021]
• NACI interim guidance on booster COVID-19 vaccine doses in Canada [10-29-2021]
• For immunization providers: Interim national vaccine storage, handling and transportation guidelines for ultra-low temperature and frozen temperature COVID-19 vaccines [09-22-2021]
• COVID-19 immunization: federal, provincial and territorial statement of common principles [modified 08-11-2021]
• Planning guidance for administration of COVID-19 vaccine [12-21-2020]
• Canada’s COVID-19 immunization plan: saving lives and livelihoods [no date]
• Recommendations on the duration of the post-vaccination observation period for influenza vaccination during the COVID-19 pandemic [10-14-2020]
• Interim guidance on continuity of immunization programs during the COVID-19 pandemic [05-13-2020]

Provinces and territories (other than Ontario)
• BC Pfizer Pediatric Vaccine Shipping, Storage, Thawing and Use Guidelines (Orange/Maroon cap) [09-22-2022]
• BC COVID-19 mRNA vaccine Comirnaty™ (Pfizer-BioNTech) [updated 10-11-2022]
• BC COVID-19 vaccine eligibility [updated 10-11-2022]
• Spikevax™ (Moderna) [updated 10-11-2022]
• BC Vaxzevria™/COVISHIELD (AstraZeneca/Verity Pharmaceuticals) [updated 09-14-2022]
• BC COVID-19 vaccine ChAdOx1-S [recombinant] [updated 09-14-2022]
• BC COVID-19 vaccine Nuvaxovid™ (Novavax) [updated 09-14-2022]
• BC COVID-19 vaccine Ad26.COV2.S [recombinant] (Janssen) [updated 09-08-2022]
• BC Guidance for receiving and handling the Pfizer-BioNTech COVID-19 mRNA vaccine (including dry ice procedures) [updated 10-11-2022]
• BC World Health Organization (WHO) emergency use authorization (EUA) qualified COVID-19 vaccines [updated 07-27-2022]
• BC Pfizer redistribution guidelines [updated 07-20-2022]
• BC Immunization manual appendix A: informed consent (page 4) [updated 07-20-2022]
• BC COVID-19 Pfizer vaccine shipping, storage, thawing and use guidelines [updated 07-20-2022]
• BC Moderna redistribution guidelines [updated 07-20-2022]
• BC Janssen shipping, storage and use guideline [updated 06-15-2022]
• BC Novavax shipping, storage and use guidelines [03-04-2022]
• BC Novavax redistribution guidelines [03-04-2022]
• BC Immunization manual: summary of changes: admin circular [03-04-2022]
• BC COVID-19 vaccine screening checklist [02-25-2022]
• BC Point of care risk assessment (PCRA) [no date]
• BC Janssen redistribution guidelines [01-17-2022]
• BC Regulated and unregulated health professionals SARS-CoV-2 immunization order [01-09-2022]
• BC Emergency medical assistants SARS-CoV-2 immunization order [updated 01-09-2022]
• BC Administrative circular [12-31-2021]
• BC 2021/22 seasonal influenza vaccine eligibility [10-00-2021]
• BC Latex content in vaccines [10-00-2021]
• BC COVID-19 vaccination: why your 2nd dose is important [08-27-2021]
• BC Vaccine SOP: cold chain incident reporting process [updated 07-21-2021]
• BC Pfizer vaccine sub dose vial reporting [07-13-2021]
• BC COVID-19 Pfizer vaccine partial tray ULT distribution guidelines [05-19-2021]
• BC Cold chain assets warranty contact information [05-05-2021]
• BC Vaccine SOP: return of materials to manufacturers [04-30-2021]

WHO
• Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing [08-18-2022]
• Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine [06-06-2022]
• Annexes to the interim recommendations for use of the Janssen Ad26.COV2.S vaccine [06-06-2022]
• COVID-19 and mandatory vaccination: ethical considerations and caveats [05-30-2022]
• COVID-19 vaccine introduction and deployment costing tool (CVIC tool) version 2.3 [04-21-2022]
• Injection safety in the context of coronavirus disease (COVID-19) vaccination: addendum to policy brief, 5 April 2022 [04-05-2022]
• Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19 [03-15-2022]
• Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm [updated 03-15-2022]
• Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac [03-15-2022]
• Annexes to the interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19: grading of evidence – evidence to recommendations tables [03-15-2022]
• Annexes to the interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience) [03-15-2022]
• Annexes to the recommendations for use of the Sinovac-CoronaVac vaccine against COVID-19: grading of evidence, evidence to recommendation tables [03-15-2022]
- Interim recommendations for use of the ChAdOx1-S (recombinant) vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™) [03-15-2022]
- Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19 [updated 02-23-2022]
- NVX-CoV2373 recombinant, adjuvanted COVID-19 vaccine [02-09-2022]
- COVAXIN® (BBV152) – Inactivated, COVID-19 vaccine [01-10-2022]
- Guidance on operational microplanning for COVID-19 vaccination [11-16-2021]
- Annexes to WHO interim recommendations for use of the COVID-19 vaccine BIBP [10-28-2021]
- Coadministration of seasonal inactivated influenza and COVID-19 vaccines: interim guidance [10-21-2021]
- How to manage COVID-19 vaccines without VVM at vaccination service points? [08-31-2021]
- Training on handling, storing and transporting Pfizer BioNTech COVID-19 Vaccine COMIRNATY® (Tozinameran) [08-04-2021]
- Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines [06-01-2021]
- Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19: [06-01-2021]
- Technical note on delayed shipments for the ChAdOx1-S (recombinant) vaccines: what are the implications for the administration of second doses?: Scientific brief [05-26-2021]
- Health worker communication for COVID-19 vaccination flow diagram [05-13-2021]
- AstraZeneca ChAdOx1-S/nCoV-19 (recombinant), COVID-19 vaccine: COVID-19 vaccine explainer [05-10-2021]
- AstraZeneca ChAdOx1-S (recombinant), COVID-19 vaccine [05-10-2021]
- Estimating COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalizations associated with laboratory-confirmed SARS-CoV-2: an evaluation using the test-negative design [05-07-2021]
- COVID-19 exercise programme - drills for vaccine deployment [05-03-2021]
- Why are there extra doses of vaccine in the vaccine vial? [04-16-2021]
- Data for action: achieving high uptake of COVID-19 vaccines: interim guidance [04-01-2021]
- Immunization as an essential health service: guiding principles for immunization activities during the COVID-19 pandemic and other times of severe disruption [11-01-2020]

CDC
- COVID-19 vaccine boosters [updated 10-24-2022]
- Stay up to date with your COVID-19 vaccines [updated 10-24-2022]
- Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic [updated 09-23-2022]
- Understanding viral vector COVID-19 vaccines [updated 09-16-2022]
- COVID-19 vaccination program operational guidance [updated 08-11-2022]
- COVID-19 vaccine reporting systems [updated 07-19-2022]
- **COVID-19 vaccination clinical & professional resources** [updated 05-13-2022]
- **Communication resources for COVID-19 vaccines** [12-11-2021]
- **Public health investigations of COVID-19 vaccine breakthrough cases: case investigations protocol** [no date]
- **Interim guidance for routine and influenza immunization services during the COVID-19 pandemic** [04-15-2021]
- **Expanding COVID-19 vaccine distribution to primary care providers to address disparities in immunization** [04-14-2021]

**UK**

- **COVID-19 vaccination: information for healthcare practitioners** [10-10-2022]
- **COVID-19 vaccination: vaccine product information** [10-03-2022]
- **COVID-19 vaccination programme** [updated 09-07-2022]
- **Monitoring reports of the effectiveness of COVID-19 vaccination** [09-01-2022]
- **National protocol for COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant])** [04-01-2022]
- **National protocol for Comirnaty® 30microgram/dose COVID-19 mRNA vaccine** [04-01-2022]
- **National protocol for Spikevax (formerly COVID-19 vaccine Moderna)** [04-01-2022]
- **COVID-19 vaccination: blood clotting information for healthcare professionals** [updated 02-14-2022]
- **COVID-19 vaccination: booster dose resources** [updated 02-02-2022]
- **National protocol for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech)** [11-20-2021]
- **COVID-19 vaccination: what to expect after vaccination** [updated 11-09-2021]
- **Monitoring of the effectiveness of COVID-19 vaccination** [09-14-2021]
- **COVID-19: vaccine surveillance strategy** [03-29-2021]

**ECDC**

- **Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA** [updated 09-08-2022]
- **COVID-19: recommendations for those vaccinated with vaccines not authorized by Health Canada for those staying in Canada to live, work or study** [modified 08-05-2022]
- **Updated joint statement from ECDC and EMA on additional booster doses of COVID-19 vaccines** [07-11-2022]
- **Public health considerations and evidence to support decisions on the implementation of a second mRNA COVID-19 vaccine booster dose** [04-28-2022]
- **Interim analysis of COVID-19 vaccine effectiveness against severe acute respiratory infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 30 years and older, ECDC multi-country study – second update** [03-14-2022]
- **Generic protocol for COVID-19 vaccine effectiveness studies during outbreaks in semi-closed settings in the EU/EEA** [12-14-2021]
- **Facilitating COVID-19 vaccination acceptance and uptake in the EU/EEA** [10-15-2021]
- **Infographic: facilitating COVID-19 vaccination acceptance and uptake** [10-15-2021]
• Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with severe acute respiratory infection laboratory-confirmed with SARS-CoV-2, version 1.0 [10-08-2021]
• Interim public health considerations for the provision of additional COVID-19 vaccine doses [09-01-2021]
• Partial COVID-19 vaccination, vaccination following SARS-CoV-2 infection and heterologous vaccination schedule: summary of evidence [07-22-2021]
• Countering online vaccine misinformation in the EU/EEA [06-29-2021]

Australia
• Clinical recommendations for COVID-19 vaccines [updated 10/24/2022]
• ATAGI recommendations on the use of a booster dose of COVID-19 vaccine [updated 10/24/2022]
• ATAGI clinical guidance for COVID-19 vaccine providers [updated 09-28-2022]
• COVID-19 vaccination – ATAGI guidance on the use of multi-dose vials for COVID-19 vaccination [08-31-2022]
• COVID-19 vaccination – vaccine dose policy [updated 07-13-2022]
• COVID-19 vaccination – updated provider kit for general practices [12-14-2021]

Vaccinations- Specific populations

Canada (Federal)
• An Advisory CommitteeStatement (ACS) National Advisory Committeeon Immunization (NACI) Recommendations on the use of Pfizer-BioNTechComirnaty (3 mcg) COVID-19 vaccine in children 6 months to 4 years of age [ 10-21-2022]
• Updated guidance on COVID-19 vaccines for individuals who are pregnant or breastfeeding[ 09-09-2022]
• Quick reference guide on use of COVID-19 vaccines for children 5 to 11 years of age: overview [modified 08-11-2022]
• Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age [07-14-2022]
• Summary of NACI statement of July 14, 2022 [07-14-2022]
• NACI rapid response: guidance on the use of booster COVID-19 vaccine doses in adolescents 12 to 17 years of age[archived] [modified 06-29-2022]
• NACI rapid response: updated guidance on COVID-19 vaccination timing for individuals previously infected with SARS-CoV-2 [archived] [modified 06-29-2022]
• NACI updated recommendations on the use of COVID-19 vaccines in children 5 to 11 years of age [archived] [modified 03-17-2022]
• Planning for the 2021-2022 school year in the context of COVID-19 vaccination [modified 02-10-2022]
• Archived: National Advisory Committee on Immunization (NACI) statement: recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5 to 11 years of age [updated 01-25-2022]

• NACI rapid response: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]

• Summary of NACI rapid response of December 3, 2021: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]

Provinces and territories (other than Ontario)

• BC COVID-19 mRNA vaccine Comirnaty™ (Pfizer-BioNTech) adult/adolescent [updated 10-11-2022]

• BC Health professionals COVID-19 vaccination status information and preventive measures – June 10, 2022 [06-10-2022]

• BC Residential care COVID-19 vaccination status [02-28-2022]

WHO

• Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons [10-26-2021]

• Update on WHO Interim recommendations on COVID-19 vaccination of pregnant and lactating women [06-10-2021]

• Disability considerations for COVID-19 vaccination: WHO and UNICEF policy brief, 19 April 2021 [04-26-2021]

CDC

• COVID-19 vaccines for children and teens [updated 10-24-2022]

• COVID-19 vaccines while pregnant or breastfeeding [updated 10-20-2022]

• COVID-19 vaccines for people who would like to have a baby [updated 07-14-2022]

• Resources to promote the COVID-19 vaccine for children & teens [09-13-2022]

• COVID-19 vaccine information for specific groups [06-19-2022]

• COVID-19 vaccine equity for racial and ethnic minority groups [03-29-2022]

• Guidance for vaccinating older adults and people with disabilities: ensuring equitable covid-19 vaccine access [01-20-2022]

• Guidance for vaccinating older adults and people with disabilities at vaccination sites [08-10-2021]

• Interim guidance for health departments: COVID-19 vaccination implementation for people experiencing homelessness [04-30-2021]

UK

• COVID-19 vaccination: women of childbearing age, currently pregnant or breastfeeding [10-03-2022]

• COVID-19 vaccination: resources for children aged 5 to 11 years [03-28-2022]

• COVID-19 vaccination: resources for children and young people aged 12 to 17 years [02-01-2022]
• COVID-19 vaccination: guide for adults [01-19-2022]
• Interim public health considerations for COVID-19 vaccination of children aged 5-11 years [12-01-2021]
• Safety of COVID-19 vaccines when given in pregnancy [04-30-2021]

ECDC
• Data collection on COVID-19 outbreaks in closed settings: long-term care facilities, version 2.1 [02-18-2022]
• COVID-19 vaccine effectiveness in adolescents aged 12–17 years and interim public health considerations for administration of a booster dose [02-08-2022]
• Interim public health considerations for COVID-19 vaccination of adolescents in the EU/EEA [06-01-2021]

Vaccinations- Adverse Effects

Canada (Federal)
• National Advisory Committee on Immunization (NACI): rapid response: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]
• Reports of myocarditis and pericarditis after COVID-19 vaccination: communiqué to health practitioners (June 3, 2021) [06-14-2021]

Provinces and territories (other than Ontario)
• BC Guidance document on the management of inadvertent vaccine errors [02-04-2022]
• BC Myocarditis/pericarditis in association with receipt of mRNA COVID-19 vaccine [06-11-2021]
• BC COVID-19 vaccine planning guide for people who are pregnant or breastfeeding [10-12-2021]
• BC Summary of AEFI reporting criteria for COVID-19 vaccination for older children, adolescents and adults [no date]

CDC
• Reported Adverse Events [updated 10-17-2022]
• COVID-19 vaccine side effects in children and teens [updated 09-14-2022]
• Possible side effects after getting a COVID-19 vaccine [updated 09-14-2022]
• Interim considerations: preparing for the potential management of anaphylaxis after COVID-19 vaccination [updated 09-02-2022]
• Lab tests to collect shortly after severe allergic reaction/anaphylaxis following COVID-19 vaccination [08-09-2021]

WHO
• How to manage COVID-19 vaccines without VVM at vaccination service points? [08-31-2021]
• COVID-19 vaccines: safety surveillance manual. Module on safety surveillance of COVID-19 vaccines in pregnant and breastfeeding women [07-12-2021]
- How to monitor and report COVID-19 vaccine side effects [03-15-2021]

**UK**
- COVID-19 vaccination: myocarditis and pericarditis information for healthcare professionals [updated 10-07-2022]
- COVID-19 vaccination: myocarditis and pericarditis information for healthcare professionals [03-21-2022]
- Myocarditis and pericarditis after COVID-19 vaccination [03-21-2022]
- COVID-19 vaccination: Guillain-Barré syndrome information for healthcare professionals [12-17-2021]
- Safety of COVID-19 vaccines when given in pregnancy [04-30-2021]

**Australia**
- COVID-19 vaccination – guidance on myocarditis and pericarditis after mRNA COVID-19 vaccines [09-23-2022]
- ATAGI clinical guidance on COVID-19 vaccine administration errors [09-07-2022]
- COVID-19 vaccination – primary care approach to thrombosis with thrombocytopenia syndrome after COVID-19 AstraZeneca vaccine [03-01-2022]

**Background Information/Case Definitions**

**Ontario Ministry of Health**
- Ontario case definition - coronavirus disease (COVID-19) [06-00-2022]

**PHAC**
- National case definition: coronavirus disease (COVID-19) [updated 10-03-2022]
- COVID-19 case report form [updated 09-09-2022]

**CDC**
- Coronavirus disease 2019 (COVID-19) 2020 interim case definition, approved August 5, 2020 [04-16-2021]

**WHO**
- WHO COVID-19 Case definition [updated 07-22-2022]
- Revised case report form for confirmed Novel Coronavirus COVID-19 (report to WHO within 48 hours of case identification) [updated 07-22-2022]
- A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 [10-06-2021]

**ECDC**
- Reinfecion with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA [04-08-2021]

**UK**
- COVID-19: epidemiology, virology and clinical features [05-17-2022]
- COVID-19: background information [05-17-2022]

Back to Top
Australia
- COVID-19 disease, symptoms and variants [updated 10-14-2022]

Other
- BMJ best practice COVID-19 [updated regularly]

Laboratories

Ontario Ministry of Health
- Management of cases and contacts of COVID-19 in Ontario (version 15) [updated 08-31-2022]

PHAC
- Biosafety advisory: SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2) [07-05-2022]
- Requirements for serological antibody tests submitted under the COVID-19 interim order: guidance [04-12-2022]
- Polymerase chain reaction (PCR) and cycle threshold (Ct) values in COVID-19 testing [06-10-2021]
- National polymerase chain reaction (PCR) testing indication guidance for COVID-19 [10-07-2020]

WHO
- Operational considerations to expedite genomic sequencing component of GISRS surveillance of SARS-CoV-2 [03-30-2021]
- Acknowledgements: the Unity Studies for sero-epidemiological investigation of COVID-19 [03-24-2022]
- Laboratory biosafety guidance related to coronavirus disease (COVID-19) [01-28-2021]
- COVID-19 new variants: knowledge gaps and research [01-12-2021]
- Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health [01-08-2021]
- SARS-CoV-2 genomic sequencing for public health goals [01-08-2021]
- SARS-CoV-2 antigen-detecting rapid diagnostic tests: an implementation guide [12-21-2020]
- Assessment tool for laboratories implementing SARS-CoV-2 testing [10-23-2020]
- Diagnostic testing for SARS-CoV-2: interim guidance [09-11-2020]
- Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays [09-11-2020]

CDC
- Interim guidelines for collecting, handling, and testing clinical specimens for COVID-19 [updated 07-17-2022]
- Testing strategies for SARS-CoV-2 [05-05-2022]
- How to report COVID-19 laboratory data [04-04-2022]
- Guidance for SARS-CoV-2 point-of-care and rapid testing [04-04-2022]
- Guidance for reporting SARS-CoV-2 sequencing results [03-21-2022]
- Evaluation for SARS-CoV-2 testing in animals [03-30-2022]
- Guidance for general laboratory safety practices during the COVID-19 pandemic [03-02-2022]
- Using antibody tests for COVID-19 [02-24-2022]
- Interim guidelines for COVID-19 antibody testing: interim guidelines for COVID-19 antibody testing in clinical and public health settings [01-24-2022]
- Interim laboratory biosafety guidelines for handling and processing specimens associated with coronavirus disease 2019 (COVID-19) [12-13-2021]
- Science brief: SARS-CoV-2 infection-induced and vaccine-induced immunity [10-29-2021]
- Lab tests to collect shortly after severe allergic reaction/anaphylaxis following COVID-19 vaccination [08-09-2021]
- Interim guidance for use of pooling procedures in SARS-CoV-2 diagnostic and screening testing [06-30-2021]
- Variants and genomic surveillance for SARS-CoV-2 [04-02-2021]
- Resources for laboratories working on coronavirus (COVID-19) [03-28-2021]
- Information for laboratories about coronavirus (COVID-19) [03-28-2021]

UK
- Outcome of the evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices) [07-11-2022]
- National standardised test performance process for manufacturers of SARS-CoV-2 virus antibody tests [07-11-2022]
- Protocol for evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices) [07-11-2022]
- Technical validation protocol for SARS-CoV-2 nucleic acid detection [07-11-2022]
- COVID-19: guidance for sampling and for diagnostic laboratories [03-29-2021]

ECDC
- The use of antibody tests for SARS-CoV-2 in the context of Digital Green Certificates [05-10-2021]

Australia
- PHLN guidance on laboratory testing for SARS-CoV-2 (the virus that causes COVID-19) [01-28-2022]

Miscellaneous Guidelines

PHAC
- Summary of evidence supporting COVID-19 public health measures [08-31-2022]
- Individual public health measures [updated 08-12-2022]
- COVID-19 and people with disabilities in Canada [07-06-2022]
• Federal/provincial/territorial public health response plan for ongoing management of COVID-19 [04-08-2022]

Canadian provinces and territories (other than Ontario)
• BC COVID-19 ethical decision-making framework [12-24-2020]

WHO
• Summary: Consolidated financing framework for ACT-accelerator agency and in-country needs [02-16-2022]
• Consolidated financing framework for ACT-A agency & in-country needs [02-09-2022]
• ACT-Accelerator 'fair share asks' - by country [02-09-2022]
• WHO technical consultation on oxygen access scale-up for COVID-19 [07-14-2021]
• Modelling the health impacts of disruptions to essential health services during COVID-19: Module 1: Understanding modelling approaches for sexual, reproductive, maternal, newborn, child and adolescent health, and nutrition [07-09-2021]
• Considerations in adjusting public health and social measures in the context of COVID-19: interim guidance [06-14-2021]
• Critical preparedness, readiness and response actions for COVID-19: interim guidance [05-27-2021]

CDC
• Return to work criteria for healthcare personnel with SARS-CoV-2 infection (interim guidance) [09-23-2022]
• Public health guidance for potential COVID-19 exposure associated with travel [updated 09-08-2022]
• Wildfire smoke and COVID-19 [08-02-2022]
• RRT composition: COVID-19 considerations [03-01-2021]

ECDC
• One-day in-action review (IAR) protocol in the context of COVID-19 [03-00-2021]
• Behavioural Insights research to support the response to COVID-19: a survey of implementation in the EU/EEA [02-17-2021]

Other
• Public health ethics and COVID-19: selected resources – National Collaborating Centre for Healthy Public Policy [11-30-2021]

Data & Surveillance
Canada
• COVID-19 data trends [modified 10-21-2022]
• Mathematical modelling and COVID-19 [modified 04-01-2022]
• National surveillance guidelines for coronavirus disease (COVID-19) [03-19-2021]

WHO
• Public health surveillance for COVID-19: interim guidance [updated 07-22-2022]
• Environmental surveillance for SARS-COV-2 to complement public health surveillance – Interim Guidance [04-14-2022]
• WHO COVID-19 essential supplies forecasting tool (COVID-ESFT) [02-15-2022]
• End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance: revised interim guidance [01-31-2022]
• Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for Member States [01-21-2022]

CDC
• Wastewater surveillance data reporting & analytics [updated 10-04-2022]
• National wastewater surveillance system (NWSS) [03-21-2022]
• Wastewater surveillance testing methods [01-26-2022]
• Public health interpretation and use of wastewater surveillance data [01-26-2022]
• Developing a wastewater surveillance sampling strategy [01-26-2022]
• Targeted wastewater surveillance at facilities, institutions, and workplaces [01-26-2022]
• COVID-19 serology surveillance [03-11-2021]
• Data visualization [02-16-2021]
• Large-scale geographic seroprevalence surveys [10-02-2020]

ECDC
• Organisation of vector surveillance and control in Europe [12-13-2021]
• Surveillance of COVID-19 in long-term care facilities in the EU/EEA [11-29-2021]
• Epidemiological update: Omicron variant of concern (VOC) – data as of 29 November 2021 (12:30) [11-29-2021]
• COVID-19 variants: genomically confirmed case numbers [11-29-2021]
• Threat assessment brief: implications of the emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA [11-26-2021]
• COVID-19 surveillance guidance - transition from COVID-19 emergency surveillance to routine surveillance of respiratory pathogens [10-18-2021]
• Guidance for representative and targeted genomic SARS-CoV-2 monitoring [05-03-2021]

UK
• COVID-19 surveillance in school KIDs (sKIDs): pre and primary schools [09-04-2020]
- Investigation of SARS-CoV-2 variants: technical briefings [updated 10-07-2022]
- SARS-CoV-2 variants of public health interest [updated 10-07-2022]

**ECDC**
- Methods for the detection and characterisation of SARS-CoV-2 variants – first update [updated 08-02-2022]
- Implications of the emergence and spread of the SARS-CoV-2 variants of concern BA.4 and BA.5 for the EU/EEA [06-13-2022]
- Technical guidance for antigenic SARS-CoV-2 monitoring [06-07-2022]
- Assessment of the further emergence of the SARS-CoV-2 Omicron VOC in the EU/EEA, 19th update [01-27-2022]
- Threat assessment brief: implications of the further emergence and spread of the SARS CoV 2 B.1.1.529 variant of concern (Omicron) for the EU/EEA first update [12-02-2021]
- Epidemiological update: Omicron variant of concern (VOC) – data as of 30 November 2021 (12.00) [11-30-2021]
- Threat assessment brief: implications of the emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA [11-26-2021]

**WHO**
- Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for member states [updated 01-21-2022]

**Testing**

**Canada**
- Interim guidance on the use of rapid antigen detection tests for the identification of SARS-CoV-2 infection [07-07-2022]
- Pan-Canadian COVID-19 testing and screening guidance: technical guidance and implementation plan [09-08-2021]
- Guidance for repeated PCR testing in individuals previously positive for COVID-19 [12-08-2020]
- National polymerase chain reaction (PCR) testing indication guidance for COVID-19 [10-07-2020]

**Ontario Ministry of Health**
- COVID-19 test requisition [06-12-2021]
- Considerations for privately-initiated testing, version 3.0 [05-21-2021]
- COVID-19 guidance: considerations for rapid antigen screening, Version 2.0 [02-17-2021]
- Considerations for employer rapid antigen screening pilot [11-20-2020]

**Canadian provinces and territories (other than Ontario)**
- BC Infection prevention and control guidance for test collection and assessment centres [09-09-2021]
- BC Antibody testing (serology) page [no date]

**WHO**
Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing [03-09-2022]

CDC

Overview of testing for SARS-CoV-2 (COVID-19) [updated 09-28-2022]
Testing strategies for SARS-CoV-2 [05-05-2022]
Guidance for antigen testing for SARS-CoV-2 for healthcare providers testing individuals in the community [04-04-2022]
Guidance for SARS-CoV-2 point-of-care and rapid testing [04-04-2022]
Using antibody tests for COVID-19 [02-24-2022]
CDC’s diagnostic test for COVID-19 only and supplies [08-17-2021]
CDC diagnostic tests for covid-19 [08-07-2021]
Nucleic acid amplification tests (NAATs) [06-14-2021]
Guidance for healthcare workers about COVID-19 (SARS-CoV-2) testing [06-14-2021]
Performing broad-based testing for SARS-CoV-2 in congregate correctional, detention, and homeless service settings [03-29-2021]
Serology testing for COVID-19 at CDC [11-03-2020]

UK

Investigation of SARS-CoV-2 variants: technical briefings [updated 10-07-2022]
How tests and testing kits for coronavirus (COVID-19) work [updated 10-07-2022]
SARS-CoV-2 variants of public health interest [updated 10-07-2022]
Investigation of SARS-CoV-2 variants of concern: variant risk assessments [06-24-2022]
SARS-CoV-2 variant of concern diagnostic assurance [04-14-2022]
Testing for coronavirus (COVID-19) before hospital [03-08-2022]
Coronavirus COVID-19 serology and viral detection tests: technical validation reports [updated 02-18-2022]
Investigation of SARS-CoV-2 variants of concern: technical briefings [09-17-2021]
Investigation of SARS-CoV-2 variants of concern – variant risk assessments for SARS-CoV-2 variant, Delta, 8 July 2021 [07-16-2021]
Investigation of SARS-CoV-2 variants of concern – variant risk assessments for SARS-CoV-2 variant, Lambda, 8 July 2021 [07-16-2021]
SARS-CoV-2 RNA testing: assurance of positive results during periods of low prevalence [10-16-2020]

ECDC

Methods for the detection and identification of SARS-CoV-2 variants- first update [08-02-2022]
A scoping review of point-of-care testing devices for infectious disease surveillance, prevention and control [04-27-2022]
- Assessment of point-of-care testing devices for infectious disease surveillance, prevention and control – a mapping exercise [04-27-2022]
- Considerations for the use of antibody tests for SARS-CoV-2 – first update [02-10-2022]
- Rapid assessment of antigenic characterisation capability and capacity for SARS-CoV-2 viruses in EU/EEA laboratories [12-20-2021]
- Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK [10-26-2021]
- Considerations on the use of rapid antigen detection (including self-) tests for SARS-CoV-2 in occupational settings [05-06-2021]
- Considerations for the use of saliva as sample material for COVID-19 testing [05-03-2021]
- Considerations on the use of self-tests for COVID-19 in the EU/EEA [03-17-2021]
- Guidance for COVID-19 quarantine and testing of travellers [03-12-2021]
- Detection and characterisation capability and capacity for SARS-CoV-2 variants within the EU/EEA [02-16-2021]
- Risk assessment: SARS-CoV-2 - increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update [02-15-2021]
- COVID-19 testing strategies and objectives [09-18-2020]
- Objectives for COVID-19 testing in school settings [08-10-2020]

Australia
- PHLN and DCNA joint statement on SARS-CoV-2 rapid antigen tests [06-20-2022]
- PHLN guidance on laboratory testing for SARS-CoV-2 (the virus that causes COVID-19) [01-28-2022]

Symptoms/Treatment

Canada
- Considerations for the use of nirmatrelvir/ritonavir to treat COVID-19 in the context of limited supply [06-22-2022]
- COVID-19 for health professionals: treatments [02-01-2022]
- Non-contact infrared thermometers (NCIT) [01-28-2021]

Ontario Ministry of Health
- Management of cases and and contacts of COVID-19 in Ontario version 15 [updated 08-31-2022]
- COVID-19 patient screening guidance document version 5.0 [08-26-2021]

BC
- Clinical Practice Guide for the Use of Therapeutics in Mild-Moderate COVID-19 [updated 10-14-2022]
- Therapy in adult pregnant patients with COVID-19 [updated 09-07-2022]
WHO

- COVID-19 disease in children and adolescents: scientific brief, 29 September 2021 [09-29-2021]
- Neurology and COVID-19: scientific brief, 29 September 2021 [09-29-2021]
- WHO living guideline: drugs to prevent COVID-19 [03-02-2021]
- Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts: interim guidance [08-12-2020]

CDC

- Clinical Care Information for COVID-19 [updated 10-19-2022]
- Caring for post-COVID conditions [updated 09-01-2022]
- Ending home isolation for persons with COVID-19 not in healthcare settings [08-31-2022]
- Ending isolation and precautions for people with COVID-19: interim guidance [08-31-2022]
- If you are sick or caring for someone [08-11-2022]
- Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare providers [06-15-2022]
- Clinical care quick reference for COVID-19 [03-16-2022]
- Care for breastfeeding people: interim guidance on breastfeeding and breast milk feeds in the context of covid-19 [02-25-2022]

WHO

- Therapeutics and COVID-19 [07-14-2022]
- COVID-19 clinical care pathway (CARE): confirm, assess, respond, evaluate [02-04-2022]
- COVID-19 clinical care pathway (CARE): confirm SARS-CoV-2 infection, assess symptoms, risk factors and severity, respond with appropriate care and treatment, evaluate clinical response and recovery [02-04-2022]
- Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection [07-15-2021]
- Hypertension and COVID-19 [06-17-2021]
- WHO information note: COVID-19 considerations for tuberculosis (TB) care [05-05-2021]
COVID-19 Diagnosis in Children

Canada
- COVID-19 signs, symptoms and severity of disease: multisystem inflammatory syndrome - children (MIS-C) [06-22-2022]

WHO

CDC
- Information for Pediatric Healthcare Providers [10-19-2022]
- Information for healthcare providers about multisystem inflammatory syndrome in children (MIS-C) [05-20-2021]

Other
- BC Children with immune compromise [08-02-2022]
- American Academy of Pediatrics What is the case definition of multisystem inflammatory syndrome in children (MIS-C) interim guidance [06-10-2022]
- BC Pediatric clinical guidance for COVID-19 [09-27-2021]
- BC Guidance for newborn care, resuscitation procedures and lactation [06-11-2021]
- BC Management of severe respiratory illness in pediatric patients during the COVID-19 pandemic [05-12-2021]

Post-COVID-19 Condition

Canada
- Post COVID-19 condition (long COVID) [updated 10-20-2022]

Ontario
- Ontario Health Post COVID-19 condition: guidance for primary care [12-00-2021]
- BC Living with persistent Post-COVID-19 symptoms
- Science Table Understanding the post COVID-19 condition (long COVID) and the expected burden for Ontario [09-14-2021]

WHO
- Evaluating and caring for patients with post-COVID conditions: interim guidance [updated 10-22-2021]
- Expanding our understanding of post COVID-19 condition: report of a WHO webinar - 9 February 2021 [04-24-2021]

CDC
- Post-COVID conditions: information for healthcare providers [updated 09-22-2021]
- Post-COVID conditions; CDC Science [09-02-2022]
- Caring for post-COVID conditions [09-01-2022]
- Evaluating and caring for patients with post-COVID conditions: interim guidance [06-14-2021]

UK
- Long-term effects of coronavirus (long COVID) [08-09-2022]

Case Investigation & Contact Tracing

Canada
- Public health management of cases and contacts associated with COVID-19 [08-18-2022]

Ontario
- Management of cases and contacts of COVID-19 in Ontario (version 15) [08-31-2022]

WHO
- Contact tracing and quarantine in the context of the Omicron SARS-CoV-2 variant: interim guidance [02-17-2022]

CDC
- Ending home isolation for persons with COVID-19 not in healthcare settings [08-31-2022]
- Quarantine and isolation [08-11-2022]
- Contact tracing resources for health departments [03-25-2022]
- Contact tracer’s interview tool: notifying people about an exposure to COVID-19 [02-28-2022]
- Interim guidance on developing a covid-19 case investigation & contact tracing plan: overview [02-28-2022]
- Prioritizing case investigations and contact tracing for covid-19 in high burden jurisdictions [02-28-2022]
- Contact tracing for COVID-19 [02-10-2022]
- Investigating a COVID-19 case [01-21-2022]
- COVID-19 contact tracing communications toolkit for health departments [11-05-2021]
- Global contact tracing [01-15-2021]

UK
- COVID-19 rapid guideline: managing COVID-19 NICE guideline [NG191] [07-14-2022]
People with symptoms of a respiratory infection including COVID-19 [06-10-2022]

Infection Prevention and Control

PHAC / Health Canada

- Coronavirus disease (COVID-19): prevention and risks [08-12-2022]
- COVID-19: Guidance on indoor ventilation during the pandemic [07-05-2022]
- Federal/provincial/territorial public health response plan for ongoing management of COVID-19 [04-08-2022]
- Update with consideration of Omicron – interim COVID-19 infection prevention and control in the health care setting when COVID-19 is suspected or confirmed– December 23, 2021 [12-24-2021]
- At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19 [12-15-2021]

Ontario

- COVID-19 guidance: personal protective equipment (PPE) for health care workers and health care entities version 1.0 [06-10-2022]

Canadian provinces and territories (other than Ontario)

- BC COVID-19: outbreak management protocol for acute care settings [02-02-2022]

WHO

- Roadmap to improve and ensure good indoor ventilation in the context of COVID-19 [03-01-2021]

CDC

- Considerations for inpatient obstetric healthcare settings [11-19-2021]
- Cleaning and disinfecting your facility: every day and when someone is sick [11-15-2021]

UK

- Ventilation of indoor spaces to stop the spread of coronavirus (COVID-19) [08-02-2022]
Section II: Guidelines for Health Sectors

Healthcare Providers

Ontario Ministry of Health

- Management of cases and and contacts of COVID-19 in Ontario version 15 [08-31-2022]
- COVID-19 guidance: acute care v.8 [06-11-2022]
- COVID-19 guidance: personal protective equipment (PPE) for health care workers and health care entities version 1.0 [06-10-2022]

Canada

- COVID-19 pandemic guidance for the health care sector: 4.3 human resources [04-22-2020]

WHO

- COVID-19 home care bundle for health care workers [02-09-2022]
- Global pulse survey on continuity of essential health services during the COVID-19 pandemic [02-07-2022]
- Third round of the global pulse survey on continuity of essential health services during the COVID-19 pandemic [02-07-2022]

CDC

- Interim guidance for managing healthcare personnel with SARS-CoV-2 infection or exposure to SARS-cov-2 [09-23-2022]
- Staff shortages [09-23-2022]
- Operational considerations for the identification of healthcare workers and inpatients with suspected COVID-19 in non-U.S. healthcare settings [01-14-2022]

UK

- COVID-19: managing healthcare staff with symptoms of a respiratory infection [08-31-2022]

Congregate Living (including Long-Term Care, Prisons, and Shelters)

Ontario Ministry of Health

- COVID-19 screening tool for long-term care homes and retirement homes: version 13 [08-31-2022]
• Ministry for seniors and accessibility COVID-19 guidance document for retirement homes in Ontario [06-24-2022]

PHAC
• Infection prevention and control for COVID-19: interim guidance for long term care homes [01-25-2022]
• COVID-19: guidance on pets and long-term care homes [07-20-2021]
• Using ventilation and filtration to reduce aerosol transmission of COVID-19 in long-term care homes [04-12-2021]
• COVID-19 guidance for long-term care facilities and nursing homes in Indigenous communities [04-14-2020]

WHO
• Infection prevention and control guidance for long-term care facilities in the context of COVID-19 update: interim guidance [01-08-2021]

CDC
• How to protect yourself and others [updated 10-19-2022]
• Interim infection prevention and control recommendations for healthcare personnel during the Coronavirus disease 2019 (COVID-19) pandemic [09-23-2022]
• Correctional and detention facilities [06-10-2022]
• Guidance on prevention and management of COVID-19 in correctional and detention facilities [05-03-2022]
• Interim guidance for SARS-CoV-2 testing in homeless shelters and encampments [04-06-2022]
• Investigating cases in homeless shelters [02-10-2022]
• Interim guidance on people experiencing unsheltered homelessness [02-10-2022]
• Interim guidance for homeless service providers to plan and respond to Coronavirus Disease 2019 (COVID-19) [02-10-2022]
• Interim guidance for general population disaster shelters during the COVID-19 pandemic [08-30-2021]

UK
• Infection prevention and control in adult social care: COVID-19 supplement [updated 10-11-2022]
• Covid-19 testing in homelessness, domestic abuse refuse and respite room settings [updated 08-31-2022]
• Operating principles for night shelters [08-31-2022]
• Preventing and controlling outbreaks of COVID-19 in prisons and places of detention [07-27-2022]
• Flu and acute respiratory illness in prisons and secure settings: information for staff [04-06-2022]
• Visiting someone in prison [04-01-2022]
• Data collection on COVID-19 outbreaks in closed settings with a completed vaccination programme: long-term care facilities, v. 2.1 [02-18-2022]
• Infection control in prisons and places of detention [07-01-2011]

Other
Section III: Guidelines for the Community

Travel, Transport & Borders

Ontario Ministry of Health
- Travelling during COVID-19 [07-19-2022]
- Guidance for public transit agencies and passengers in response to COVID-19 [03-21-2022]

Canada
- Official global travel advisories [updated often]

CDC
- COVID-19 travel recommendations by destination [updated regularly]
- Stay up to date with your COVID-19 vaccines including Boosters [updated 10-24-2022]
- Requirement for proof of COVID-19 vaccination for air passengers [07-14-2022]

UK
- COVID-19: guidance for people whose immune system means they are at higher risk [updated 10-07-2022]
- People with symptoms of a respiratory infection including COVID-19 [06-10-2022]
- Coronavirus (COVID-19): advice for heavy goods (HGV) and public service vehicle (PSV) operators [03-29-2022]
- Coronavirus (COVID-19): cruise ship travel [03-17-2022]

Schools / Childcare

Ontario Ministry of Health
- Management of cases and contacts of COVID-19 in Ontario version 15 [08-31-2022]
- COVID-19: health and safety measures for child care [08-17-2022]

PHAC
- Planning for the 2021-2022 school year in the context of COVID-19 vaccination [02-10-2022]

CDC
- Guidance for K-12 schools and childcare programs [08-11-2022]
- Schools, child care, and colleges [08-11-2022]

UK
- Emergency planning and response for education, childcare, and children's social care settings [updated 10-03-2022]
Mental Health /Addiction

Ontario Ministry of Health


Provinces & Territories (excluding Ontario)

- QC The roles of public health in population mental health and wellness promotion [10-03-22]
- QC Housing and social inequalities in health in times of COVID-19: strategies for promoting affordable quality housing [04-05-2022]
- QC Preventing violence and suicide within the context of the COVID-19 pandemic: courses of action [04-05-2022]
- QC Preventing loneliness in young adults in the context of a pandemic [04-05-2022]
- BC Impacts of the COVID-19 pandemic on the health and wellbeing of young adults in British Columbia [07-00-2021]
- QC Public health ethics and COVID-19: selected resources [11-00-2021]

WHO

- Mental health and COVID-19: early evidence of the pandemic’s impact: scientific brief, 2 March 2022 [03-02-2022]
- Rise, respond, recover: renewing progress on women’s, children’s and adolescent’s health in the era of COVID-19 [12-00-2021]
- Social isolation and loneliness among older people: advocacy brief [07-29-2021]
- Smoking and COVID-19 [06-30-2020]
- Addressing violence against children, women and older people during the COVID-19 pandemic: key actions [06-18-2020]
- COVID-19 and violence against women: what the health sector / system can do [04-07-2020]

SAMHSA

- Disaster planning handbook for behavioural health service programs [03-00-2021]
- Considerations for the care and treatment of mental and substance use disorders in the COVID-19 epidemic: March 20, 2020 [05-07-2020]
- Intimate partner violence and child abuse considerations during COVID-19 [no date]

UK

- Alcohol and drug misuse prevention and treatment guidance [03-07-2022]
- Every Mind Matters: looking after your mental health [no date]
- Domestic abuse: how to get help [11-11-2021]

Community

Ontario Ministry of Health

- COVID-19 public health measures and advice [updated 10-12-2022]
• COVID-19 guidance: community emergency evacuations v.3 [05-16-2022]

PHAC
• Summary of evidence supporting COVID-19 public health measures [08-31-2022]
• Accessing public health support for First Nations communities [08-05-2022]
• COVID-19 and people with disabilities in Canada [07-06-2022]
• Reducing COVID-19 risk in community settings: a tool for operators [02-10-2022]
• At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19 [12-15-2021]

WHO
• WHO mass gathering COVID-19 risk assessment tool: generic events, version 3 [06-16-2022]

CDC
• Isolation and precautions for people with COVID-19 [08-11-2022]
• Information about COVID-19, pets, and other animals [04-14-2022]

UK
• Infection prevention and control in adult social care: COVID-19 supplement [updated 10-11-2022]
• Living safely with respiratory infections, including COVID-19 [06-16-2022]

Businesses/Workplaces
Ontario Ministry of Health
• COVID-19 public health measures and advice [no date]
• COVID-19 and workplace health and safety [09-14-2022]
• Outbreak guidance: workplace and living settings for seasonal international agriculture workers (IAWs) [09-08-2022]
• Guidance for employers managing workers with symptoms within 48 hours of COVID-19 immunization [11-30-2021]

WHO
• Preventing and mitigating COVID-19 at work [05-19-2021]

CDC
• Specific settings [05-27-2022]
• Protecting workers: guidance on mitigating and preventing the spread of COVID-19 in the workplace [08-13-2021]

UK
• Reducing the spread of respiratory infections, including COVID-19, in the workplace [06-10-2022]
Masks (Non-Medical)

Ontario Ministry of Health
- [Face coverings and face masks](#) [09-07-2022]

PHAC
- [COVID-19 mask use: advice for community settings](#) [04-22-2022]

WHO

CDC
- [Your guide to masks](#) [09-09-2022]

ECDC
- [Considerations for the use of face masks in the community in the context of the SARS-CoV-2 Omicron variant of concern](#) [02-07-2022]

UK
- [Living safely with respiratory infections, including COVID-19: when to consider wearing a face covering or a face mask](#) [06-16-2022]
- [The Disabled Persons Transport Advisory Committee (DPTAC) position on face coverings](#) [03-22-2021]